Clindamycin Phosphate Solution label

Clindamycin Phosphate Solution

Clindamycin Phosphate Solution Recall

Get an alert when a recall is issued.

Side Effects & Adverse Reactions

Orally and parenterally administered clindamycin has been associated with severe colitis which may result in patient death. Use of the topical formulation of clindamycin results in absorption of the antibiotic from the skin surface. Diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported with the use of topical and systemic clindamycin.

Studies indicate a toxin(s) produced by clostridia is one primary cause of antibiotic-associated colitis. The colitis is usually characterized by severe persistent diarrhea and severe abdominal cramps and may be associated with the passage of blood and mucus. Endoscopic examination may reveal pseudomembranous colitis. Stool culture for Clostridium difficile and stool assay for C. difficile toxin may be helpful diagnostically.

When significant diarrhea occurs, the drug should be discontinued. Large bowel endoscopy should be considered to establish a definitive diagnosis in cases of severe diarrhea.

Antiperistaltic agents such as opiates and diphenoxylate with atropine may prolong and/or worsen the condition. Vancomycin has been found to be effective in the treatment of antibiotic-associated pseudomembranous colitis produced by Clostridium difficile.The usual adult dosage is 500 mg to 2 grams of vancomycin orally per day in three to four divided doses administered for 7 to 10 days. Cholestyramine or colestipol resins bind vancomycin in vitro.If both a resin and vancomycin are to be administered concurrently, it may be advisable to separate the time of administration of each drug.

Diarrhea, colitis, and pseudomembranous colitis have been observed to begin up to several weeks following cessation of oral and parenteral therapy with clindamycin.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Uses

Clindamycin Phosphate Topical Solution USP, 1% is indicated in the treatment of acne vulgaris. In view of the potential for diarrhea, bloody diarrhea and pseudomembranous colitis, the physician should consider whether other agents are more appropriate. (See CONTRAINDICATIONS , WARNINGS and ADVERSE REACTIONS.)

History

There is currently no drug history available for this drug.

Other Information

Clindamycin Phosphate Topical Solution USP, 1% contains clindamycin phosphate, at a concentration equivalent to 10 mg clindamycin per milliliter. Each Clindamycin Phosphate Topical Solution pledget applicator contains approximately 1 mL of topical solution.

The solution contains isopropyl alcohol 50% v/v, propylene glycol, and purified water. Clindamycin phosphate is a water soluble ester of the semi-synthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent antibiotic lincomycin.

The structural formula is represented below:Chemical Structure

The chemical name for clindamycin phosphate is: Methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-threo-α-D-galacto-octopyranoside 2-(dihydrogen phosphate). pH between 4.0 and 7.0.

Clindamycin Phosphate Solution Manufacturers

  • Clindamycin Phosphate Solution | Rebel Distributors Corp
    No Recall

    Clindamycin Phosphate Solution | Rebel Distributors Corp

    Clindamycin Phosphate Solution | Rebel Distributors Corp

    Use a Clindamycin Phosphate Topical Solution pledget for the application of clindamycin phosphate twice daily to affected area.

    More than one pledget may be used. Each pledget should be used only once and then be discarded. Remove pledget from foil just before use. Do not use if the seal is broken. Discard after single use.

  • Physicians Total Care, Inc.
    Clindamycin Phosphate Solution | Physicians Total Care, Inc.
    No Recall

    Clindamycin Phosphate Solution | Physicians Total Care, Inc.

    Clindamycin Phosphate Solution | Physicians Total Care, Inc.

    Do not use if the seal on jar is broken. Remove pledget from jar just before use. Use a pledget to apply a thin film of Clindamycin Phosphate Topical Solution to the affected area twice daily. More than one pledget may be used. Each pledget should be used only once and then discarded. Keep jar tightly closed when not in use.

  • Perrigo New York Inc
    Clindamycin Phosphate Solution | Perrigo New York Inc
    No Recall

    Clindamycin Phosphate Solution | Perrigo New York Inc

    Clindamycin Phosphate Solution | Perrigo New York Inc

    Apply a thin film of Clindamycin Phosphate Topical Solution USP, 1% to the affected area twice daily. Keep container tightly closed.

  • Perrigo New York Inc
    Clindamycin Phosphate Solution | Perrigo New York Inc
    No Recall

    Clindamycin Phosphate Solution | Perrigo New York Inc

    Clindamycin Phosphate Solution | Perrigo New York Inc

    Do not use if the seal on jar is broken. Remove pledget from jar just before use. Use a pledget to apply a thin film of Clindamycin Phosphate Topical Solution to the affected area twice daily. More than one pledget may be used. Each pledget should be used only once and then discarded. Keep jar tightly closed when not in use.

  • Taro Pharmaceuticals U.s.a., Inc.
    Clindamycin Phosphate Solution | Taro Pharmaceuticals U.s.a., Inc.
    No Recall

    Clindamycin Phosphate Solution | Taro Pharmaceuticals U.s.a., Inc.

    Clindamycin Phosphate Solution | Taro Pharmaceuticals U.s.a., Inc.

    Apply a thin film of Clindamycin Phosphate Topical Solution twice daily to affected area.

    Keep all liquid dosage forms in containers tightly closed.

  • Versapharm Incorporated
    Clindamycin Phosphate Solution | Cardinal Health
    No Recall

    Clindamycin Phosphate Solution | Cardinal Health

    Clindamycin Phosphate Solution | Cardinal Health

    NEXIUM is supplied as delayed-release capsules for oral administration or in packets for preparation of delayed-release oral suspensions. The recommended dosages are outlined in Table 1. NEXIUM should be taken at least one hour before meals.

    The duration of proton pump inhibitor administration should be based on available safety and efficacy data specific to the defined indication and dosing frequency, as described in the prescribing information, and individual patient medical needs. Proton pump inhibitor treatment should only be initiated and continued if the benefits outweigh the risks of treatment.

    Table 1: Recommended Dosage Schedule of NEXIUM

    Indication

    Dose

    Frequency

    Gastroesophageal Reflux Disease (GERD)

    Healing of Erosive Esophagitis

    20 mg or 40 mg

    Once Daily for 4 to 8 Weeks

    Maintenance of Healing of Erosive Esophagitis

    20 mg

    Once Daily

    Symptomatic Gastroesophageal Reflux Disease

    20 mg

    Once Daily for 4 Weeks

    Pediatric GERD

    12 to 17 Year Olds

    Healing of Erosive Esophagitis

    Symptomatic GERD

    20 mg or 40 mg

    20 mg

    Once Daily for 4 to 8 Weeks

    Once Daily for 4 Weeks

    1 to 11 Year Olds

    Short-term Treatment of Symptomatic GERD

    10 mg

    Once Daily for up to 8 Weeks

    Healing of Erosive Esophagitis

    weight < 20 kg

    10 mg

    Once Daily for 8 Weeks

    weight ≥ 20 kg

    10 mg or 20 mg

    Once Daily for 8 Weeks

    1 month to < 1 year old

    Erosive esophagitis due to acid-mediated GERD

    weight 3 kg to 5 kg

    2.5 mg

    Once Daily for up to 6 Weeks

    weight > 5 kg to 7.5 kg

    5 mg

    Once Daily for up to 6 Weeks

    weight >7.5 kg to 12 kg

    10 mg

    Once Daily for up to 6 Weeks

    Risk Reduction of NSAID-Associated Gastric Ulcer

    20 mg or 40 mg

    Once Daily for up to 6 months

    H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence

    Triple Therapy:

    NEXIUM

    40 mg

    Once Daily for 10 Days

    Amoxicillin

    1000 mg

    Twice Daily for 10 Days

    Clarithromycin

    500 mg

    Twice Daily for 10 Days

    Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome

    40 mg

    Twice Daily

    a) [See Clinical Studies (14.1)] The majority of patients are healed within 4 to 8 weeks. For patients who do not heal after 4 to 8 weeks, an additional 4 to 8 weeks of treatment may be considered.

    b) Controlled studies did not extend beyond six months.

    c) If symptoms do not resolve completely after 4 weeks, an additional 4 weeks of treatment may be considered.

    d) Doses over 1 mg/kg/day have not been studied.

    e) The dosage of NEXIUM in patients with pathological hypersecretory conditions varies with the individual patient. Dosage regimens should be adjusted to individual patient needs.

    f) Doses up to 240 mg daily have been administered [see Drug Interactions (7)].

    Please refer to amoxicillin and clarithromycin prescribing information for Contraindications, Warnings, and dosing in elderly and renally-impaired patients.

    Special Populations

    Hepatic Insufficiency

    In patients with mild to moderate liver impairment (Child Pugh Classes A and B), no dosage adjustment is necessary. For patients with severe liver impairment (Child Pugh Class C), a dose of 20 mg of NEXIUM should not be exceeded [seeClinical Pharmacology (12.3)].

    Directions for use specific to the route and available methods of administration for each of these dosage forms are presented in Table 2.

    Table 2: Administration Options

    Administration Options

    (See text following table for additional instructions.)

    Dosage Form

    Route

    Options

    Delayed-Release Capsules

    Oral

    Capsule can be swallowed whole.

    -or-

    Capsule can be opened and mixed with applesauce.

    Delayed-Release Capsules

    Nasogastric Tube

    Capsule can be opened and the intact granules emptied into a syringe and delivered through the nasogastric tube.

    For Delayed-Release Oral Suspension

    Oral

    For the 2.5 mg and 5 mg strengths, mix the contents of packet with 5 mL of water, leave 2 to 3 minutes to thicken, stir and drink within 30 minutes.

    For the 10 mg, 20 mg and 40 mg strengths, mix contents of packet with 15 mL of water, and follow the instructions above.

    For Delayed-Release Oral Suspension

    Nasogastric or Gastric Tube

    For the 2.5 mg and 5 mg strengths, add 5 mL of water to a syringe and then add contents of packet. Shake the syringe; leave 2 to 3 minutes to thicken. Shake the syringe and inject through the nasogastric or gastric tube within 30 minutes.

    For the 10 mg, 20 mg and 40 mg strengths, add 15 mL of water, and follow the instructions above.

    NEXIUM Delayed-Release Capsules

    NEXIUM Delayed-Release Capsules should be swallowed whole.

    Alternatively, for patients who have difficulty swallowing capsules, one tablespoon of applesauce can be added to an empty bowl and the NEXIUM Delayed-Release Capsule can be opened, and the granules inside the capsule carefully emptied onto the applesauce. The granules should be mixed with the applesauce and then swallowed immediately: do not store for future use. The applesauce used should not be hot and should be soft enough to be swallowed without chewing. The granules should not be chewed or crushed. If the granules/applesauce mixture is not used in its entirety, the remaining mixture should be discarded immediately.

    For patients who have a nasogastric tube in place, NEXIUM Delayed-Release Capsules can be opened and the intact granules emptied into a 60 mL catheter tipped syringe and mixed with 50 mL of water. It is important to only use a catheter tipped syringe when administering NEXIUM through a nasogastric tube. Replace the plunger and shake the syringe vigorously for 15 seconds. Hold the syringe with the tip up and check for granules remaining in the tip. Attach the syringe to a nasogastric tube and deliver the contents of the syringe through the nasogastric tube into the stomach. After administering the granules, the nasogastric tube should be flushed with additional water. Do not administer the granules if they have dissolved or disintegrated.

    The mixture must be used immediately after preparation.

    NEXIUM For Delayed-Release Oral Suspension

    NEXIUM For Delayed-Release Oral Suspension should be administered as follows:

    • •Empty the contents of a 2.5 mg or 5 mg packet into a container containing 5 mL of water. For the 10 mg, 20 mg, and 40 mg strengths, the contents of a packet should be emptied into a container containing 15 mL of water. • •Stir. • •Leave 2 to 3 minutes to thicken. • •Stir and drink within 30 minutes. • •If any medicine remains after drinking, add more water, stir, and drink immediately. • •In cases where there is a need to use two packets, they may be mixed in a similar way by adding twice the required amount of water or follow the mixing instructions provided by your pharmacist or doctor.

    For patients who have a nasogastric or gastric tube in place, NEXIUM For Delayed-Release Oral Suspension can be administered as follows:

    • •Add 5 mL of water to a catheter tipped syringe and then add the contents of a 2.5 mg or 5 mg NEXIUM packet. For the 10 mg, 20 mg, and 40 mg strengths, the volume of water in the syringe should be 15 mL. It is important to only use a catheter tipped syringe when administering NEXIUM through a nasogastric tube or gastric tube. • •Immediately shake the syringe and leave 2 to 3 minutes to thicken. • •Shake the syringe and inject through the nasogastric or gastric tube, French size 6 or larger, into the stomach within 30 minutes. • •Refill the syringe with an equal amount of water (5 mL or 15 mL). • •Shake and flush any remaining contents from the nasogastric or gastric tube into the stomach.